Dive deeper
Open any topic for the full explanation, tables, clinical checkpoints, and references.
Full-length video Where can I learn more about telling a benign lesion from skin cancer?
What is the dermatologist trying to decide?
Start Here: What Are We Trying to Decide?
A skin lesion is simply an area of skin that looks or feels different from the surrounding skin. It may be a flat patch, a raised bump, a mole, a scaly area, a sore, or a growth. The word lesion does not mean cancer.
The first distinction is between benign and malignant:
- Benign means noncancerous. Examples include most moles, seborrheic keratoses, angiomas, cysts, and dermatofibromas.
- Malignant means cancerous. The common categories include basal cell carcinoma, cutaneous squamous cell carcinoma, and melanoma.
A clinical diagnosis is the dermatologist's best diagnosis based on the story and examination, sometimes supported by magnification or photographs. A tissue diagnosis comes from examining sampled tissue under a microscope. The two are partners, not competitors.
The short answer to the title question is therefore:
That is why expertise matters and why expertise still has limits.
Why can harmless growths and cancers look alike?
Why Harmless Growths and Cancers Can Look Alike
Skin has a limited visual vocabulary. Many unrelated conditions can become brown, pink, red, white, scaly, crusted, shiny, firm, eroded, or ulcerated. Sun exposure, inflammation, scratching, bleeding, and healing can alter the original appearance.
A harmless seborrheic keratosis may become dark and crusted after irritation. A melanoma may be small, pale, or nearly symmetric. A basal cell carcinoma may look like a pimple, scar, eczema patch, or sore that almost heals. A squamous cell carcinoma may resemble a wart or an inflamed keratosis.1–5
No single clue carries the whole diagnosis. Symmetry can reassure without proving benignity. Bleeding can occur after trauma to a benign spot but also deserves attention when spontaneous or recurrent. Dark color can occur in harmless lesions, while some melanomas contain little or no brown pigment.
Which benign lesions can resemble skin cancer?
Common Benign Mimics and Malignant Impostors
This table does not diagnose a lesion. It shows why overlap is normal and why the next step depends on the complete examination.
| Common benign lesion | Cancer it can resemble | Why the appearance can overlap |
|---|---|---|
| Seborrheic keratosis | Melanoma or squamous cell carcinoma | It may be dark, irregular, thick, crusted, inflamed, or partly detached. |
| Benign nevus (mole) | Melanoma | Both arise from melanocytes and may be brown or raised; change and discordance with the person's other moles matter. |
| Angioma | Amelanotic melanoma or another vascular-appearing tumor | Both may be red, purple, or prone to bleeding after trauma. Dermoscopic vessel patterns can help separate them. |
| Dermatofibroma | Melanoma, scar-like basal cell carcinoma, or another firm tumor | It may be pigmented, firm, tender, or scar-like. A classic stable pattern is reassuring; rapid growth or ulceration is not. |
| Scar | Morpheaform basal cell carcinoma | Both may be pale, firm, smooth, or poorly defined. A “scar” without a convincing injury history deserves scrutiny. |
| Eczema or psoriasis patch | Superficial basal cell carcinoma or squamous cell carcinoma in situ | All can be pink, scaly, itchy, and persistent. Failure to behave like the presumed rash lowers confidence. |
| Actinic keratosis | Squamous cell carcinoma | Both occur on sun-damaged skin and may be rough or tender; thickness, rapid growth, pain, and deeper firmness raise concern. |
| Wart or inflamed cyst | Squamous cell carcinoma | Each can be thick, tender, crusted, or rapidly noticeable. Persistent growth and palpated depth matter. |
The reverse problem is equally important: cancer can imitate a familiar benign lesion. Melanoma can resemble a mole, seborrheic keratosis, bruise, angioma, or nail injury. Basal cell carcinoma can resemble a pimple or dermatitis. Squamous cell carcinoma can resemble a wart or “just a scab.”1–5
How does a dermatologist evaluate a lesion?
The Dermatologist's Actual Diagnostic Sequence
Dermatologists narrow uncertainty in a deliberate order. Not every visit requires every tool, but the reasoning usually follows this sequence.
1. History: what has the spot done?
The dermatologist asks when the lesion appeared and whether it has changed in size, shape, color, thickness, surface, or symptoms. Repeated spontaneous bleeding, persistent pain, rapid growth, ulceration, or a sore that returns after seeming to heal can change the urgency.2–5
History also prevents false alarms. A stable bright-red angioma present for years has a different story from a new enlarging red nodule. A crust after a known scratch has a different story from recurrent unexplained crusting.
2. Symptoms and change: is the behavior coherent?
“Evolution” is often more useful than a frozen description. The ABCDE melanoma checklist—Asymmetry, Border irregularity, Color variation, Diameter, and Evolution—is a prompt for attention, not a clearance test. Nodular, amelanotic, acral, and small melanomas may not satisfy the classic pattern.1,4
Itching alone is nonspecific. Pain, tenderness, numbness, tingling, weakness, or persistent bleeding can become more important when they agree with a suspicious examination.
3. Whole-patient context: what is the baseline risk?
The same-looking spot carries different meaning in different patients. The dermatologist considers personal skin-cancer history, family history of melanoma, immune suppression, cumulative sun exposure, prior radiation, number and pattern of moles, age, medications, and whether the lesion is arising in a scar or chronic wound.2–5
Risk does not diagnose the spot. It changes the threshold for reassurance, monitoring, or tissue sampling.
4. Examination and comparison: does the lesion belong?
The lesion is examined in good light and compared with the patient's other spots. The ugly-duckling principle asks whether it departs from that person's usual pattern. A mole that would be ordinary on one patient may be strikingly different on another.
Comparison also helps identify field patterns. Several similar waxy papules support seborrheic keratoses. One firm, changing outlier among otherwise similar lesions deserves more attention.
5. Palpation: what does touch add?
Palpation means examining by touch. It reveals firmness, depth, fixation, tenderness, scale, and whether the process extends beyond the visible surface. A photograph cannot show that a “flat” spot is indurated underneath or that a nodule feels tethered to deeper tissue.2,3
When clinically indicated, the examination may also include nearby nerves or lymph nodes. That is not routine for every harmless-appearing spot; it is part of evaluating a lesion whose suspected diagnosis or symptoms make those findings relevant.
6. Dermoscopy: what pattern appears under magnification?
Dermoscopy uses a handheld lighted magnifier that reduces surface reflection and reveals pigment, vessels, keratin, and other structures not visible to the naked eye. In trained hands, it improves melanoma detection and helps distinguish many benign and malignant patterns.6,7
Dermoscopy is not a microscope for living tissue and does not produce a pathology diagnosis. Its value depends on training, the lesion type, and integration with the rest of the examination.
7. Serial photographs: would change over time answer the question safely?
Standardized clinical or dermoscopic photographs can document a baseline. For a carefully selected, mildly atypical flat lesion without high-concern features, short-interval monitoring may reveal meaningful change while avoiding an unnecessary procedure.8
Monitoring is a diagnostic plan, not indecision. A valid plan names the lesion, image method, interval, return date, and biopsy trigger. It fails when the patient cannot return reliably or the lesion is already too concerning to watch.
8. Biopsy: is tissue the safest way to resolve uncertainty?
A biopsy removes part or all of a lesion for microscopic examination. It becomes the decisive step when the clinical diagnosis is uncertain enough to affect safety or when the exact type, depth, or growth pattern will determine treatment.2–5
The biopsy technique should answer the clinical question. A suspected melanoma often needs complete sampling with enough depth to measure Breslow thickness when feasible. A possible invasive squamous cell carcinoma needs a sample deep enough to assess invasion. A basal cell carcinoma may require a representative sample even when the clinical diagnosis seems likely because subtype can change treatment.4,9–11
What does each diagnostic step add—and not prove?
What Each Diagnostic Step Adds—and Cannot Prove
| Tool or step | What it adds | What it cannot prove by itself |
|---|---|---|
| History and symptoms | Time course, change, bleeding, pain, prior treatment, and behavior | The exact cell type under the microscope |
| Whole-patient context | Baseline risk and a safer threshold for action | That a specific lesion is benign or malignant |
| Visual examination and comparison | Shape, color, surface, border, distribution, and ugly-duckling context | A definitive diagnosis when benign and malignant patterns overlap |
| Palpation | Firmness, depth, fixation, scale, tenderness, and sub-surface extension | Histologic subtype or a complete microscopic margin |
| Dermoscopy | Subsurface pigment, vessel, and keratin patterns that improve diagnostic accuracy | Histology, tumor depth, or certainty in every equivocal lesion |
| Standardized serial photographs | Objective evidence of stability or change in a carefully selected lesion | Safety for a nodular, symptomatic, rapidly changing, or otherwise high-concern lesion |
| Teledermatology photograph | Access, triage, and sometimes a useful preliminary opinion | Reliable palpation, total-body comparison, or image quality beyond what was submitted |
| Consumer app or photo classifier | A prompt that may encourage attention | Permission to ignore a changing or symptomatic lesion |
| Biopsy and dermatopathology | Tissue diagnosis and, when adequately sampled, features that direct treatment | A guarantee that a partial sample contains every component or defines the full tumor edge |
What does dermatopathology tell you?
What Dermatopathology Means
Dermatopathology is pathology focused on skin disease. The pathologist examines the tissue architecture and individual cells, often using deeper sections or special stains when needed. The report may name the diagnosis, describe cancer subtype, measure depth, identify ulceration or nerve involvement, and comment on the sampled edges.
The pathology report must still be matched to the clinical lesion. Clinicopathologic correlation means asking whether the microscopic diagnosis explains the spot that was seen and sampled.
For example:
- A pathology result of “irritated seborrheic keratosis” may fit a classic waxy lesion that was recently scratched.
- The same result may need reconsideration if the clinician thought the lesion was a firm, rapidly growing nodule and the biopsy was very superficial.
- A biopsy can correctly diagnose basal cell carcinoma yet miss an aggressive component elsewhere in a mixed tumor. One series found 18% overall subtype disagreement between biopsy and later specimen; another found an aggressive component during Mohs in 28% of tumors initially called nonaggressive on biopsy.10,11
This is not a reason to distrust pathology. It is a reason to choose the sample intelligently and reconcile the result with the original question.
How can technology help within clinical care?
Technology Helps—Within a Clinical Relationship
Teledermatology can improve access and triage, especially when images are high quality and the question is well defined. Its limits include absent palpation, incomplete views, uncertain scale, lighting differences, and lack of comparison with the rest of the patient's skin.12
Consumer apps and image classifiers can be useful reminders, but published melanoma-triage app studies were inconsistent and at high risk of bias.13 A model can analyze pixels; it cannot reliably establish that the photographed object is the correct lesion, that the image captures firmness or depth, or that a negative result is safe for the person in front of it.
Artificial intelligence may assist clinicians as tools and evidence improve. It does not remove the need for clinical context, accountability, and tissue diagnosis when the answer matters.
AI and photo-based skin tools may support triage or comparison, but they should not be used to rule skin cancer in or out.
When should a lesion be monitored, evaluated, or biopsied?
Monitor, Evaluate Soon, or Biopsy?
| Path | When it can fit | Examples of features that move away from this path | What the plan should include |
|---|---|---|---|
| Monitor with a defined interval | Mildly atypical, flat, low-concern lesion with a coherent pattern and reliable follow-up | Nodular growth, meaningful evolution, spontaneous bleeding, pain, ulceration, firmness, fixation, or clinical discordance | Standardized image, named interval, reliable return, and explicit biopsy trigger |
| Arrange in-person evaluation soon | New or changing lesion that cannot be classified safely from a photograph but lacks an immediate emergency feature | Faster growth, repeated bleeding, ulceration, neurologic symptoms, marked pain, or immune suppression may shorten the timeline | A visit that allows comparison, palpation, dermoscopy, and a biopsy decision |
| Biopsy promptly | Cancer cannot be excluded safely, the lesion is high concern, or tissue will change treatment | Do not substitute prolonged monitoring or repeated low-quality photos | Technique deep and broad enough to answer the diagnostic and staging question |
A stable, classic benign lesion may be reassured without biopsy. A changing spot does not automatically require biopsy that day. The safe choice depends on the whole pattern and the cost of being wrong.
Short-interval monitoring is a poor choice for a rapidly growing painful nodule; arrange in-person evaluation and a biopsy decision instead.
What does the evidence say about diagnostic accuracy?
Evidence by the Numbers
Evidence by the NumbersTraining and dermoscopy improve melanoma recognition
Training and dermoscopy improve melanoma recognition
76% to 92% sensitivity
- Population
- Adults with lesions selected for specialist melanoma assessment in comparative diagnostic-accuracy studies
- Outcome
- Estimated sensitivity increased from about 76% with visual inspection to about 92% with dermoscopy at a fixed specificity of 80%
- Time horizon
- At the index diagnostic assessment
What it means: Dermoscopy can help a trained clinician find more melanomas without treating every benign lesion as cancer.
Limitations: Accuracy depends on training, setting, and which lesions enter the study; dermoscopy does not replace biopsy when clinically important uncertainty remains.
References: 6
Evidence by the NumbersDefined monitoring can be safe for the right lesion
Defined monitoring can be safe for the right lesion
99.2% benign reliability
- Population
- Carefully selected mildly atypical flat lesions without nodular, symptomatic, rapidly changing, or other high-concern features
- Outcome
- No change after a three-month sequential digital dermoscopy interval strongly predicted a benign lesion
- Time horizon
- Three months
What it means: A dermatologist may reasonably photograph and recheck a low-concern flat lesion instead of biopsying every spot immediately.
Limitations: The finding does not support monitoring a nodular, symptomatic, rapidly changing, ulcerated, or otherwise high-concern lesion.
References: 8
Evidence by the NumbersA reassuring app result cannot rule out melanoma
A reassuring app result cannot rule out melanoma
7% to 73% sensitivity
- Population
- Adults using evaluated smartphone applications to triage skin lesions suspicious for melanoma
- Outcome
- Reported sensitivity ranged from 7% to 73%, corresponding to 27% to 93% of melanomas missed in the evaluated datasets
- Time horizon
- At the app's index classification
What it means: A negative consumer-app result is not permission to ignore a new, changing, symptomatic, or otherwise concerning lesion.
Limitations: Apps, datasets, and study quality varied; these historical estimates do not measure every current or future tool.
References: 13
What do common diagnostic situations look like?
Four Examples That Show How the Sequence Works
1. A waxy brown growth that became crusted
The lesion matches several longstanding seborrheic keratoses, has a classic dermoscopic pattern, and was recently scratched. Reassurance or treatment for irritation may be reasonable. If the pattern is discordant or the change is unexplained, biopsy becomes more appropriate.
2. A small pink bump that repeatedly bleeds
The spot looks ordinary in a phone photograph, but it is firm, persists, and repeatedly bleeds without trauma. Palpation and dermoscopy raise concern for basal cell carcinoma. Biopsy supplies the diagnosis that appearance alone could not.
3. A mildly atypical flat mole with no high-risk features
The mole is flat, only mildly different from the patient's other moles, and has no nodularity, symptoms, or rapid change. The patient can return reliably. A standardized short-interval dermoscopic photograph may be a deliberate alternative to immediate biopsy.
4. A rapidly growing tender nodule
The lesion is raised, painful, and enlarging. Even if its surface resembles a wart or inflamed cyst, this is not a safe “watch and see” pattern. Prompt in-person assessment and a sufficiently deep biopsy are the stronger path.
These examples show decision rules, not diagnoses. A real lesion requires its own examination.
What should I ask at the skin-lesion visit?
Questions to Ask at the Visit
- What diagnoses are you considering, and which one is most likely?
- Which part of the history or examination is most reassuring or concerning?
- What did dermoscopy add?
- Is this lesion safe to monitor? If so, for exactly how long?
- What change should trigger an earlier return?
- If we biopsy it, will the sample be deep and broad enough to answer the important question?
- If the pathology does not fit the clinical impression, how will the two be reconciled?
- Should any nearby lymph nodes, nerves, or other skin areas be examined based on the suspected diagnosis?
Frequently asked questions about lesion diagnosis
Frequently Asked Questions
Can a dermatologist diagnose a benign lesion without a biopsy?
Yes. Many benign lesions have a highly characteristic history, examination, and dermoscopic pattern. Biopsy is not required merely to prove that every harmless growth is harmless. Tissue becomes important when uncertainty remains or the exact diagnosis will change care.
Can a dermatologist be wrong from visual examination?
Yes. Dermatologic expertise improves pattern recognition and the choice of next step; it does not make overlapping diseases visually identical to their microscopic diagnosis. A good clinician states the level of confidence and uses biopsy when the remaining uncertainty matters.
Is dermoscopy the same as a biopsy?
No. Dermoscopy reveals structures beneath the surface and improves diagnostic accuracy in trained hands. A biopsy removes tissue for microscopic examination and is the reference standard when a definitive tissue diagnosis is needed.6,7
Why not biopsy every spot?
Unnecessary biopsies cause scars, discomfort, cost, anxiety, and sometimes ambiguous incidental findings. The goal is not maximum cutting; it is the right certainty for the risk. A classic benign lesion can be left alone, while a high-concern lesion should not be watched merely to avoid a scar.
Does monitoring mean the dermatologist is unsure what to do?
Not when the lesion and plan fit. Short-interval monitoring can test whether a carefully selected flat lesion changes. It becomes unsafe when the spot is nodular, symptomatic, rapidly changing, or the patient cannot return reliably.8
Can a negative app result tell me that a spot is safe?
No. Published consumer melanoma-triage apps have missed melanomas, and a photograph cannot supply palpation or whole-patient context.13 A changing, painful, bleeding, ulcerated, or otherwise concerning spot deserves professional assessment regardless of an app result.
Why can the diagnosis or subtype change after surgery?
A partial biopsy samples only part of a lesion. Mixed tumors may contain a component not present in the sample. Deeper tissue can also reveal invasion or a growth pattern that changes risk.9–11
What if the pathology result does not match what the lesion looked like?
The dermatologist and pathologist should perform clinicopathologic correlation: confirm the site, review the clinical impression and sampling depth, and decide whether deeper sections, another biopsy, slide review, or complete removal is needed.
Where should I go next in the Patient Journey?
Next Steps in the Patient Journey
If the lesion needs tissue diagnosis, continue to What Is a Skin Biopsy and What Should I Expect? If a diagnosis is already available, continue to What Does My Skin Biopsy Report Mean? Seek prompt in-person evaluation for a new, rapidly changing, painful, spontaneously bleeding, ulcerated, firm, fixed, or otherwise concerning lesion.
Continue with the question that fits you now
Who reviewed and authored this lesion-diagnosis guide?
References for this lesion-diagnosis guide
References
- Dinnes J, Deeks JJ, Chuchu N, et al. Visual inspection for diagnosing cutaneous melanoma in adults. Cochrane Database Syst Rev. 2018;12:CD013194. DOI: 10.1002/14651858.CD013194.
- Dinnes J, Deeks JJ, Chuchu N, et al. Visual inspection and dermoscopy for diagnosing keratinocyte skin cancers in adults. Cochrane Database Syst Rev. 2018;12:CD011901. DOI: 10.1002/14651858.CD011901.pub2.
- Madan V, Lear JT, Szeimies RM. Non-melanoma skin cancer. Lancet. 2010;375:673-685. DOI: 10.1016/S0140-6736(09)61196-X.
- Swetter SM, Tsao H, Bichakjian CK, et al. Guidelines of care for the management of primary cutaneous melanoma. J Am Acad Dermatol. 2019;80:208-250. PMID: 30392755. DOI: 10.1016/j.jaad.2018.08.055.
- Askari SK, Schram SE, Wenner RA, et al. Evaluation of prospectively collected presenting signs and symptoms of biopsy-proven melanoma, basal cell carcinoma, and squamous cell carcinoma. J Am Acad Dermatol. 2007;56:739-747. PMID: 17258839.
- Dinnes J, Deeks JJ, Chuchu N, et al. Dermoscopy, with and without visual inspection, for diagnosing melanoma in adults. Cochrane Database Syst Rev. 2018;12:CD011902. DOI: 10.1002/14651858.CD011902.pub2.
- Kittler H, Pehamberger H, Wolff K, Binder M. Diagnostic accuracy of dermoscopy. Lancet Oncol. 2002;3:159-165. DOI: 10.1016/S1470-2045(02)00679-4.
- Altamura D, Avramidis M, Menzies SW. Assessment of the optimal interval for and sensitivity of short-term sequential digital dermoscopy monitoring for the diagnosis of melanoma. Arch Dermatol. 2008;144:502-506.
- Ahmadi O, Das M, Hajarizadeh B, Mathy JA. Impact of shave biopsy on diagnosis and management of cutaneous melanoma: a systematic review and meta-analysis. Ann Surg Oncol. 2021;28:6168-6178. PMID: 33782802.
- Haws AL, Rojano R, Tahan SR, Phung TL. Accuracy of biopsy sampling for subtyping basal cell carcinoma. J Am Acad Dermatol. 2012;66:106-111. PMID: 21798620.
- Moon D, Randall G, Higgins S, Sutton AV, Wysong A. Misclassification of aggressive basal cell carcinoma subtypes and implications for management. Dermatol Surg. 2021. PMID: 33905389.
- Chuchu N, Dinnes J, Takwoingi Y, et al. Teledermatology for diagnosing skin cancer in adults. Cochrane Database Syst Rev. 2018;12:CD013193. DOI: 10.1002/14651858.CD013193.
- Chuchu N, Takwoingi Y, Dinnes J, et al. Smartphone applications for triaging adults with skin lesions that are suspicious for melanoma. Cochrane Database Syst Rev. 2018;12:CD013192. PMID: 30521685. DOI: 10.1002/14651858.CD013192.